Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation

Go back to Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
HERON THERAPEUTICS (NASDAQ: HRTX) Delayed: 0.32 --0 (-0%)
Previous Close $0.32    52 Week High $31.32 
Open $0.33    52 Week Low $13.95 
Day High $0.33    P/E N/A 
Day Low $0.31    EPS $-3.29 
Volume 916,760